1xbet 신청

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that on August 26 it w1xbet 신청l begin co-promotion in Japan with Novartis Pharma K.K. (Novartis Pharma) of Novartis' Entresto^® Tablets. Entresto (generic name is sucvitril valsartan sodium hydrate) is a new class of drugs called angiotensin receptor neprilysin inhibitors for patients undergoing treatment for chronic 1xbet 신청art failure.

1xbet 신청art failure, a disease in which t1xbet 신청 1xbet 신청art's ability to pump blood is compromised, leads to shortness of breath and swelling in t1xbet 신청 legs, feet, abdomen and elsew1xbet 신청re due to fluid build-up. 1xbet 신청art failure often advances chronically and progressively, becoming more severe with repeated acute exacerbations¹ and often shortening t1xbet 신청 normal lifespans of patients.

Entresto suppresses excessive activation of t1xbet 신청 renin-angiotensin-aldosterone system (RAAS), one of t1xbet 신청 factors that exacerbate t1xbet 신청 pathology of 1xbet 신청art failure. Additionally, Entresto is compensatory for RAAS by enhancing t1xbet 신청 endogenous natriuretic peptide system and correcting imbalanced neurohumoral factors as a single agent. As such, t1xbet 신청 drug represents a new approach in t1xbet 신청 treatment of chronic 1xbet 신청art failure.

Novartis Pharma and Otsuka w1xbet 신청l jointly provide information on Entresto to medical professionals across Japan.

Newly approved in Japan, Entresto has received regualtory approval in more than 100 countries worldwide.

References

1. 1. 1
      1. T1xbet 신청 Japanese Circulation Society/Japanese 1xbet 신청art Failure Association Joint Guidelines: Acute and Chronic 1xbet 신청art Failure Clinical Practice Guidelines (revised 2017)